文献速递呼吸衰竭与机械通气重症综合管理与镇静镇痛

极长时间(>50天)静脉-静脉体外膜氧合支持的结果

Outcomes of Extremely Prolonged (> 50 d) Venovenous Extracorporeal Membrane Oxygenation Support.
PubMed 文献 · Crit Care Med · 2023-03-16
一句话结论回顾性队列显示,极长时间(>50天,中位94天)静脉-静脉ECMO支持用于ARDS患者,67%成功撤机、50%桥接肺移植、88%撤机者出院,作者认为对经选择的危重患者可能可行。

该回顾性队列研究在大型三级城市医疗中心纳入2018年1月至2022年1月首次置管的18岁以上、接受静脉-静脉ECMO支持超过50天的患者。研究期间共130例患者接受静脉-静脉ECMO,其中12例接受延长(>50天)支持;11例(92%)为COVID-19继发ARDS,1例为双肺移植后细菌性肺炎继发ARDS。中位年龄39岁(IQR 35-51岁),中位ECMO支持94天(IQR 70-128天,最长180天),插管至置管中位5天(IQR 2-14天)。8例(67%)成功撤机,其中6例(50%)桥接肺移植、2例(17%)桥接恢复;成功撤机者中7例(88%)出院,出院7例在撤管后6个月均存活,有足够随访时间的5/6(83%)在撤管后1年存活。作者认为,极长时间静脉-静脉ECMO支持以允许自体肺恢复或优化肺移植,对经选择的危重患者可能是可行策略。

要点

  • 研究期间130例接受静脉-静脉ECMO,仅12例支持超过50天,中位支持94天(IQR 70-128天),最长180天。
  • 12例中11例(92%)为COVID-19继发ARDS,1例为双肺移植后细菌性肺炎继发ARDS;中位年龄39岁(IQR 35-51岁)。
  • 8例(67%)成功撤机:6例(50%)桥接肺移植、2例(17%)桥接恢复;成功撤机者7例(88%)出院。
  • 出院7例在撤管后6个月均存活;有足够随访时间的5/6(83%)在撤管后1年存活。
  • 9例(75%)在静脉-静脉ECMO支持期间成功活动;插管至置管中位5天(IQR 2-14天)。

适用人群与场景

  • 18岁及以上、因急性呼吸衰竭接受静脉-静脉ECMO支持超过50天、首次置管时间在2018年1月至2022年1月之间的患者。
  • 研究人群为大型三级城市医疗中心收治的危重患者,其中11例(92%)为COVID-19继发ARDS,1例为双肺移植后细菌性肺炎继发ARDS。

研究设计与关键结果

  • 研究类型为回顾性队列研究,单中心(大型三级城市医疗中心),研究期间共130例患者接受静脉-静脉ECMO,其中12例接受延长(>50天)支持。
  • 12例患者中位年龄39岁(IQR 35-51岁);中位静脉-静脉ECMO支持时间94天(IQR 70-128天),最长180天;插管至置管中位时间5天(IQR 2-14天)。
  • 9例(75%)在静脉-静脉ECMO支持期间成功活动。
  • 8例(67%)成功撤除静脉-静脉ECMO:6例(50%)桥接至肺移植,2例(17%)桥接至恢复。
  • 成功撤机的8例中7例(88%)出院;出院7例在撤管后6个月均存活;有足够随访时间的5/6(83%)在撤管后1年存活。

证据类型、等级与局限

  • 证据类型:回顾性队列研究。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 作者认为,极长时间静脉-静脉ECMO支持以允许自体肺恢复或为肺移植优化准备,在经选择的危重患者中可能是可行策略,进一步支持扩大静脉-静脉ECMO用于难治性呼吸衰竭。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

OBJECTIVES: There has been a sustained increase in the utilization of venovenous extracorporeal membrane oxygenation (ECMO) over the last decade, further exacerbated by the COVID-19 pandemic. We set out to describe our institutional experience with extremely prolonged (> 50 d) venovenous ECMO support for recovery or bridge to lung transplant candidacy in patients with acute respiratory failure.

DESIGN: Retrospective cohort study.

SETTING: A large tertiary urban care center.

PATIENTS: Patients 18 years or older receiving venovenous ECMO support for greater than 50 days, with initial cannulation between January 2018 and January 2022.

INTERVENTIONS: None.

MEASUREMENTS AND MAIN RESULTS: One hundred thirty patients were placed on venovenous ECMO during the study period. Of these, 12 received prolonged (> 50 d) venovenous ECMO support. Eleven patients (92%) suffered from adult respiratory distress syndrome (ARDS) secondary to COVID-19, while one patient with prior bilateral lung transplant suffered from ARDS secondary to bacterial pneumonia. The median age of patients was 39 years (interquartile range [IQR], 35-51 yr). The median duration of venovenous ECMO support was 94 days (IQR, 70-128 d), with a maximum of 180 days. Median time from intubation to cannulation was 5 days (IQR, 2-14 d). Nine patients (75%) were successfully mobilized while on venovenous ECMO support. Successful weaning of venovenous ECMO support occurred in eight patients (67%); 6 (50%) were bridged to lung transplantation and 2 (17%) were bridged to recovery. Of those successfully weaned, seven patients (88%) were discharged from the hospital. All seven patients discharged from the hospital were alive 6 months post-decannulation; 83% (5/6) with sufficient follow-up time were alive 1-year after decannulation.

CONCLUSIONS: Our experience suggests that extremely prolonged venovenous ECMO support to allow native lung recovery or optimization for lung transplantation may be a feasible strategy in select critically ill patients, further supporting the expanded utilization of venovenous ECMO for refractory respiratory failure.

来源:Crit Care Med,查看原文。版权归原作者所有。

参考来源

  1. Malas J, Chen Q, Shen T, et al. Outcomes of Extremely Prolonged (> 50 d) Venovenous Extracorporeal Membrane Oxygenation Support. Crit Care Med. 2023. PMID: 36927927. doi:10.1097/CCM.0000000000005860

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。